A Phase 4 interventional study of Dexmedetomidine Injection [Precedex] and Lidocaine IV in Analgesia, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Assiut University · Phase 4, Interventional, and Supportive care
Opioid sparing analgesia: Continuous intraoperative infusion of dexmedetomidine versus lidocaine for laparoscopic cholecystectomy, a randomized double-blind clinical trial.
Postoperative pain represents one of the most common complaints following surgeries. Despite advances in modern medicine, pain following surgical procedures is still a challenge for anesthetists, though significant progress made over the past decades. The mechanism of pain following laparoscopic procedures is thought to be multifactorial. The main causes of pain after laparoscopic cholecystectomy (LC) are pain from the incision site, pneumoperitoneum and cholecystectomy. Clinicians using different methods for analgesia after LC. like non-steroidal anti-inflammatory drugs, intraperitoneal local anesthetics, local anesthetics applied to the wound site, removal of the insufflation gas, paravertebral block (PVB), and epidural block. To date, the mainstay of management has been the administration of exogenous opioids such as morphine or fentanyl. However, pain is not always fully relieved by such agents, and often patients develop tolerance to them. The ever-increasing doses of opioids are clearly not without their adverse effects. In addition to that, many patients and even some clinicians wrongly believe that addiction can be inevitable after administration of opioids. Dexmedetomidine is an alpha 2-adrenergic agonist which is a relatively new drug used for procedural sedation. It has sedative and anxiolytic effects and is known for its analgesic potential owing to a reduction of sympathetic tone. Dexmedetomidine has dose-dependent effects, ranging from minimal to deep sedation. Moreover, except at doses that cause very deep sedation or general anesthesia, the sedation is reversible. These are unique properties among the sedative medications in common use. Dexmedetomidine does not impair the respiratory drive per se and seldom causes apnea. However, it has been shown to impair the respiratory responses to hypoxia and hypercapnia and can cause hemodynamic effects such as hypertension, hypotension and bradycardia. Systemic lidocaine has centrally and peripherally analgesic, anti-hyperalgesic and anti-inflammatory effects with reduced side-effects especially if used with appropriate dose. Recently, intravenous lidocaine infusion is considered a part of analgesic therapy regimen that decreases postoperative opioid requirements and enhances convalescence after major surgeries. Dexmedetomidine and lidocaine are common adjuvant medicine anesthetics during operation for the sedative and analgesic properties. Besides, some studies have proved that both are effective in relieving postoperative pain in adults. However, there are very limited studies comparing the effects of the two adjuvant analgesics on postoperative pain in patients undergoing laparoscopic cholecystectomy (LC).
1,190 studies on the registry are indexed under Agnosia; 508 are open to participants now.
This study's enrollment of 64 is below the median of 78 across 1,024 interventional studies indexed under Agnosia.
Browse Agnosia studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This group will receive continuous intraoperative dexmedetomidine IV infusion \[1ug/kg dexmedetomidine over 15 min as a loading dose and 0.5ug/kg/h for maintenance\].
Drug: Dexmedetomidine Injection [Precedex]
This group will receive continuous intraoperative lidocaine IV infusion \[1.5 mg/kg lidocaine over 15 min as a loading dose and 1.5 mg/kg/h for maintenance\].
Drug: Lidocaine IV
dexmedetomidine group will receive continuous intraoperative dexmedetomidine IV infusion \[1ug/kg dexmedetomidine over 15 min as a loading dose and 0.5ug/kg/h for maintenance\].The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
lidocaine group will receive continuous intraoperative lidocaine IV infusion \[1.5 mg/kg lidocaine over 15 min as a loading dose and 1.5 mg/kg/h for maintenance\]. The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
Maximum Numeric Pain Rating Scale
Numeric Pain Rating Scale (NPRS) will be explained to the patient to be able to choose the score that best expressed the intensity of pain postoperatively ranging from 0 to 10, with 0 being "no pain" and 10 being "the worst pain imaginable".
Time frame: 6 hours
Richmond Agitation-Sedation Scale
Richmond Agitation-Sedation Scale (RASS) will be used to evaluate the level of sedation in post-anesthesia care unit (PACU), It is a 10-point scale, with four levels of anxiety or agitation, one level denoting a calm and alert state, and 5 levels of sedation, ranging from +4 to -5, desirable score is 0 to -2.
Time frame: 15 minutes
First call for rescue analgesic (Nalbuphine)
Time frame: 1 day
The total postoperative Nalbuphine consumption
Time frame: 1 day
Intraoperative automated non-invasive blood pressure monitoring.
Time frame: 1 hour
Intraoperative electrocardiogram (ECG) heart rate monitoring.
Time frame: 1 hour
The mean duration of PACU stay.
Time frame: 3 hours
Side effects of study drugs.
Time frame: 1 hour
Satisfaction of the patients questionnaire
Time frame: 1 day
Plan to share: No
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University